Connect with us

Fertility

Hormone sensor could streamline IVF process

Published

on

A hormone sensor being developed in Australia could help reduce fertility treatment costs and patient pain during IVF.

When preparing for egg collection or an embryo transfer, IVF patients rely on clinicians to closely monitor hormone levels to ensure the procedure is timed precisely when progesterone, oestradiol and luteinising hormone levels are optimal, giving the patient the best chance at conception.

Currently, blood tests are the primary method of measuring progesterone levels, requiring patients to undergo multiple blood draws at a laboratory during certain stages of their menstrual cycle.

However, this approach has several limitations.

For example, if testing falls on a weekend, when most labs are closed, IVF providers are forced to choose a less optimal testing time, potentially affecting treatment precision.

University of Melbourne alumni Edgar Charry and Muhammad Umer, whose partners have lived experience of infertility, created a reproductive health solution by developing a biosensor that can detect progesterone and oestradiol levels using fluid found in the skin, rather than in the blood.

Their startup company Symex Labs has partnered with the University of Melbourne to translate their research into a commercial product.

“Previous research shows nearly all hormones that exist in blood, are also present in interstitial fluid,” said Symex Labs co-founder Charry.

“Interstitial fluid is clear fluid just under the skin that sits between cells, delivering nutrients and carrying away waste.”

“Our biosensor will eventually be worn as a patch and will work by penetrating the skin using small microneedles to attract progesterone molecules in the patient’s interstitial fluid.

“These molecules will bind to the surface of the probe, generating electrical activity. The technology then translates the electrical activity to progesterone levels, ultimately informing the IVF clinical team if the patient is ready for embryo transfer.

“This data will be sent directly to the clinic’s monitoring system, allowing IVF nurses to review the results and advise the patient.”

Monash IVF research director associate professor Mark Green said that, for Monash IVF, the investment in Symex Labs aligns with the company’s focus on innovation and improving the patient journey.

“This technology will save patients time and money as they can conveniently wear the patch in the comfort of their own home, resulting in fewer visits to the clinic and fewer painful injections,” associate professor Green said.

“The biosensor would also be a gamechanger for women living in regional areas, who often have to travel long distances for blood draws.”

As the exact amount of progesterone in interstitial fluid is not well understood, Symex Labs is conducting a world-first clinical study at Monash IVF to establish baseline levels by benchmarking them against concentrations measured in blood samples.

Researchers say their hormone tracking technology also has wider clinical applications beyond the IVF sector.

“Our wearable hormone biosensor has strong potential well beyond fertility care, particularly in PCOS management, perimenopause and menopause symptom management, where continuous hormone insight can replace today’s indirect, symptom-based tracking,” said Symex Labs co-founder Muhammad Umer.

“By integrating directly with consumer health apps, the technology can enable personalised, data-driven management of chronic hormonal conditions and life-stage transitions that currently lack real-time biomarkers.

“For example, if a woman’s oestrogen is going up and down constantly, that’s often a sign that she is getting into that stage, so having access to this health information could help women implement lifestyle changes earlier.”

The research has received A$2.5m in funding from the federal government, the University of Melbourne’s Genesis fund, Monash IVF, RMIT and Breakthrough Victoria.

The first in-human pilot study is expected to get underway within the next 12 months, with commercialisation plans slated for early 2028.

Fertility

Weight loss surgery improves menstrual health and PMOS symptoms, study finds

Published

on

Weight loss surgery was linked to more regular periods and fewer polyendocrine metabolic ovarian syndrome (PMOS) symptoms in women aged 18 to 45 living with obesity in a recent study.

The researchers recommend that women undergoing the procedure have access to preconception care and reproductive counselling to support their reproductive health.

Researchers at the University of Surrey analysed data over 24 months from 84 women who underwent bariatric surgery and 18 women living with obesity who did not have surgery.

Of those who underwent surgery, 49 had gastric bypass procedures and 35 had gastric sleeve surgery.

Women who underwent metabolic bariatric surgery lost more than 30kg on average at 12 and 24 months after the procedure.

Among women with polycystic ovaries, the condition persisted in only 10 per cent after 24 months.

Women also reported a resolution of clinical hirsutism, or excess body hair, by 12 months.

Women who had previously experienced irregular periods reported more regular menstrual cycles after surgery.

Professor Martin Whyte, co-author of the study and professor of metabolic medicine at the University of Surrey, said: “A large proportion of those undergoing bariatric surgery are women of reproductive age, who may be planning a pregnancy in the coming years.

“So much remains unknown about the impact of this type of surgery on women who are planning to have children.

“This raises the question of when the ideal time after surgery is to conceive.”

Women have a higher prevalence of obesity than men, with 57 per cent of women in the UK classified as overweight and 27 per cent living with obesity, which can affect fertility and the health of an unborn baby.

The researchers said 17 women had healthy pregnancies following surgery.

Although this was not specifically examined in the study, no difference in birth weight was observed between babies conceived within or after the first year.

Dr Kathryn Hart, co-author of the study and associate professor in nutrition and dietetics at the University of Surrey, said: “What we have found is that bariatric surgery positively affects the reproductive health of women living with obesity and can improve the likelihood of them having a healthy pregnancy after surgery.

“Dysregulated hormone levels, irregular periods and conditions such as polycystic ovaries are affected by obesity.

“By reducing this, what we have seen is that it can lead to improvements without the need for medication.

“We would suggest that clinicians consider medical intervention for obesity to treat irregularities in the menstrual cycle and issues with fertility.”

Continue Reading

Fertility

Scottish gov to consider IVF for single women

Published

on

The Scottish government has launched a national review into whether NHS IVF access should be extended to single women.

The review will also consider whether wider access should be offered to couples who have children from previous relationships.

Health secretary Angela Constance said: “Access to NHS IVF treatment should be fair, timely and reflect the way people’s lives and families look today.”

Most single women are not currently eligible for NHS IVF treatment in Scotland.

Campaigners have welcomed the review.

Katie Rollings of Fertility Action said: “It’s an essential and long-awaited decision that will impact a huge number of people who are struggling to grow their families.

She said there is “no evidence” that having two parents rather than one determines whether a child will thrive.

She added: “What matters is whether a child is loved, safe, supported and has stable, positive relationships around them.”

Figures from the Human Fertilisation and Embryology Authority show Scotland is the only UK nation where NHS-funded IVF cycles outnumber privately funded cycles.

In 2024, more than 6,000 cycles of fertility treatment were carried out among more than 4,000 patients in Scotland. Both figures were slightly lower than the record highs recorded in 2022.

The past 20 years have also seen a rise in the number of same-sex female couples and single women receiving fertility treatment.

In 2024, 625 IVF cycles were carried out for women in same-sex couples in Scotland, with more than one third funded by the NHS.

There were 330 cycles involving single women, of which 50 were NHS-funded.

In England, single women can access IVF through the NHS, although eligibility varies according to the local health trust’s policy.

Current Scottish rules state that couples are eligible if they have been living in a stable relationship for two years and neither partner has been sterilised.

Couples where one partner already has a child can be eligible, but those where both partners have children from previous relationships are not.

Eligibility rules also require a body mass index above 18.5 and below 30, and state that couples must not smoke, drink alcohol or take drugs during treatment. The mother must be under 42.

The Scottish government said the review would also examine consistency of access to fertility preservation, including during cancer treatment, as well as reducing waiting times for donor eggs and sperm.

Same-sex female couples already have access to NHS IVF, but they can face long waits for donor eggs or sperm, as can heterosexual couples who require donor treatment.

The National Fertility Group will lead the review and make “costed, demand-modelled recommendations”, which are due to be published by early summer 2027.

The group will include fertility experts from Scotland’s four NHS-assisted conception units in Glasgow, Edinburgh, Aberdeen and Dundee.

Prof Sarah Martins Da Silva, an NHS consultant and chair of fertility medicine at Dundee University, said there were questions to be answered in a resource-stretched NHS.

“As a fertility specialist I’m never going to be disappointed if the criteria is widened,” she said.

“But with single people, as an NHS clinician looking at the competing demands we have, I’d ask the question about whether being single is a health condition that needs to be funded.”

Da Silva said NHS waiting lists were full of couples who require donated eggs or sperm because of medical conditions including cancer and could face longer waits.

“It’s slightly a disservice to them,” she said.

“There would need to be a real investment and resource without making everybody wait an extraordinary long time.

“With the current financial environment we work in, if you’re talking about new money, where would that come from?”

She said she would welcome changes that encouraged more people to donate eggs or sperm and questioned whether arguments about children needing two parents were necessarily relevant to the debate.

“On the one hand bringing up a child is quite an expensive process, and if you don’t have that support, it can be very difficult.

“But on the other hand, many people start off as a couple and divorce.”

Da Silva also welcomed plans for the review to consider eligibility for couples who already have children, describing the move as “fantastic”.

Continue Reading

Fertility

NHS IVF access review launched in Scotland

Published

on

Scotland has launched a review of NHS IVF access, including whether treatment should extend to single women and couples with children from previous relationships.

The national review will assess how fertility services can better reflect modern family structures while maintaining fair and consistent access across Scotland.

It will also examine access to fertility preservation services, particularly for women who have undergone cancer treatment, and ways to cut waiting times for patients who need donor eggs or sperm.

Scotland currently offers the most comprehensive nationwide NHS IVF provision in the UK. Eligible patients can access up to three full cycles of IVF treatment through the NHS, subject to existing eligibility criteria.

Ministers will also consider updated clinical guidance from the National Institute for Health and Care Excellence.

The revised recommendations suggest patients who have not achieved a successful pregnancy after three IVF cycles could benefit from up to three additional NHS-funded treatment cycles.

The review is part of the Scottish Government’s commitment to examining how fertility services are delivered and whether they meet patients’ needs across Scotland.

Scottish health secretary Angela Constance said: “Access to NHS IVF treatment should be fair, timely and reflect the way people’s lives and families look today, and delivering this review is one of our key 100 day commitments.

“The review will look closely at the current system, including waiting times for those who need donor eggs or sperm for their treatment.

“This work builds on annual Scottish Government funding, which has supported the expansion of NHS IVF treatment over the past ten years.”

Healthcare leaders and fertility specialists will be watching closely as the review progresses, with any future changes potentially broadening access to treatment and addressing long-standing concerns around equity, consistency and waiting times.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.